{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATRA", "query": { "intervention": "ATRA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 188, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ATRA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T19:47:59.623Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02339740", "title": "Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA" ], "interventions": [ { "name": "Arsenic Trioxide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 158, "start_date": "2015-07-21", "completion_date": "2029-06-30", "has_results": true, "last_update_posted_date": "2026-02-18", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 152, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02339740" }, { "nct_id": "NCT03312634", "title": "An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibrodysplasia Ossificans Progressiva" ], "interventions": [ { "name": "Palovarotene", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clementia Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 107, "start_date": "2017-11-30", "completion_date": "2022-09-07", "has_results": true, "last_update_posted_date": "2023-11-29", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 4, "location_summary": "San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312634" }, { "nct_id": "NCT06274164", "title": "Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "RAI1 Gene 17P11.2 Deletion+Duplication" ], "interventions": [ { "name": "Electroencephalography/Polysomnography (EEG/PSG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Skin Biopsy", "type": "PROCEDURE" }, { "name": "Blood draw", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Month", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Month to 80 Years" }, "enrollment_count": 90, "start_date": "2024-03-13", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06274164" }, { "nct_id": "NCT00276601", "title": "Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "5 Years to 74 Years" }, "enrollment_count": null, "start_date": "2004-10", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Gainesville, Florida • Atlanta, Georgia + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00276601" }, { "nct_id": "NCT02965456", "title": "Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne" ], "interventions": [ { "name": "IDP 121 Lotion", "type": "DRUG" }, { "name": "IDP-121 Vehicle Lotion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "9 Years", "maximum_age": null, "sex": "ALL", "summary": "9 Years and older" }, "enrollment_count": 820, "start_date": "2015-11-04", "completion_date": "2017-02-23", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 34, "location_summary": "Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965456" }, { "nct_id": "NCT00112502", "title": "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Glioblastoma Multiforme" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2005-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 12, "location_summary": "Fort Smith, Arkansas • Orlando, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112502" }, { "nct_id": "NCT00028106", "title": "131MIBG to Treat Malignant Pheochromocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma" ], "interventions": [ { "name": "[131]I-MIBG", "type": "DRUG" }, { "name": "6-[18F]Fluorodopamine", "type": "DRUG" }, { "name": "[123]I-MIBG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 32, "start_date": "2001-12-05", "completion_date": "2007-01-08", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028106" }, { "nct_id": "NCT00003598", "title": "UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer", "Precancerous/Nonmalignant Condition" ], "interventions": [ { "name": "tretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "FEMALE", "summary": "14 Years and older · Female only" }, "enrollment_count": 180, "start_date": "1999-01", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2010-09-22", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003598" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT03427554", "title": "To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Tretinoin cream 0.1%", "type": "DRUG" }, { "name": "RETIN-A® Cream", "type": "DRUG" }, { "name": "Vehicle of the test product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 455, "start_date": "2017-08-21", "completion_date": "2018-01-26", "has_results": false, "last_update_posted_date": "2018-05-18", "last_synced_at": "2026-09-02T19:47:59.623Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03427554" } ] }